GlassScriptPhysician profile
Anne P Mclaughlin
NPI 1972670156
$12,065.33
in general payments reported to CMS, 2019-2025
42 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $854 · 2021: $1,379 · 2022: $1,766 · 2023: $3,084 · 2024: $1,934 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,745 · Consulting Fee: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.04 |
| Consulting Fee | $1,215.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,713.02 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,519.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $1,185.00 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $1,061.13 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $1,016.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $972.38 | 2019-2025 | Dupixent |
| Amgen INC. | $387.51 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $335.63 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $326.93 | 2020-2025 | Takhzyro |
| Grifols USA, LLC | $309.38 | 2019-2024 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $274.59 | 2019-2025 | |
| Pharming Healthcare, INC. | $266.96 | 2019-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $266.35 | 2021-2025 | Orladeyo |
| Galderma Laboratories, L.P. | $223.22 | 2025 | Nemluvio |
| Kaleo, INC. | $219.30 | 2019-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $208.75 | 2019-2024 | |
| Pfizer INC. | $170.06 | 2020-2022 | |
| Alk-Abello, INC | $166.96 | 2019-2023 | Alternaria Tenuis, Pre-Pen, Timothy, Standardized |
| Covis Pharma Gmbh | $165.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $153.29 | 2019-2022 | |
| Aerin Medical INC. | $148.43 | 2020 | |
| Abbvie INC. | $126.60 | 2022-2025 | |
| Genentech, INC. | $99.05 | 2023-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $87.55 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $81.73 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $64.99 | 2022 | |
| Shire North American Group INC | $51.97 | 2019 | |
| Lilly USA, LLC | $50.39 | 2025 | Ebglyss |
| Biocryst Pharmaceuticals, INC. | $49.43 | 2020 | |
| Hikma Pharmaceuticals USA | $46.00 | 2023-2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $45.80 | 2021-2023 | |
| Verona Pharma, INC. | $40.85 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.95 | 2019-2021 | |
| Octapharma USA, INC. | $34.75 | 2021-2024 | Cutaquig |
| Hospira, INC. | $23.46 | 2024 | |
| Horizon Therapeutics Plc | $22.72 | 2022 | |
| Leo Pharma INC. | $22.06 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.02 | 2025 | Xhance, Nuzyra |
| Incyte Corporation | $18.77 | 2022 | |
| Uswm, LLC | $17.00 | 2021 | |
| Cycle Pharmaceuticals INC | $16.50 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.